Form 424B3 - Prospectus [Rule 424(b)(3)]
2024年8月14日 - 5:30AM
Edgar (US Regulatory)
Filed
pursuant to 424(b)(3)
Registration
Statement No. 333-277190
PROSPECTUS
SUPPLEMENT NO. 6
(To
Prospectus dated April 3, 2024)
Microbot
Medical Inc.
1,005,965
Shares of Common Stock
This
prospectus supplement (this “Prospectus Supplement”) is being filed to update and supplement our prospectus dated April 3,
2024, as supplemented (the “Prospectus”), relating to the resale of up to 1,005,965 shares of our common stock, $0.01 par
value per share, representing shares held by the selling stockholders named in the Prospectus, including their transferees, pledgees,
donees or successors.
Specifically,
this Prospectus Supplement is being filed to update and supplement the information included in the Prospectus with certain information
reported by us with the Securities and Exchange Commission. Accordingly, we have included such information in this Prospectus Supplement
below. Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this
Prospectus Supplement modifies or supersedes such statement.
Capitalized
terms used but not defined herein have the meanings ascribed to them in the Prospectus.
This
Prospectus Supplement is not complete without, and may not be utilized except in connection with, the Prospectus, including any supplements
and amendments thereto.
We
may further amend or supplement the Prospectus and this Prospectus Supplement from time to time by filing amendments or supplements as
required. You should read the entire Prospectus, this Prospectus Supplement and any amendments or supplements carefully before you make
your investment decision.
Our
common stock is listed on The Nasdaq Capital Market under the symbol “MBOT”. On August 12, 2024, the closing price of our
common stock was $0.9747.
Investing
in our common stock involves significant risks. You should read the section entitled “Risk Factors” beginning on page 11
of the Prospectus for a discussion of certain risk factors that you should consider before investing in our common stock.
Neither
the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these
securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this Prospectus Supplement is August 13, 2024
The
Company entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future
collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory University will
assume the responsibility of exploring the feasibility of integrating the LIBERTY® Endovascular Robotic Surgical System
with an imaging system to create an autonomous robotic system for endovascular procedures.
The
Company received ISO 13485:2016 certification for its quality management system, which is required to obtain CE mark approval for sales
in the European Union. In addition, in view of the recent revision published by the U.S. Food & Drug Administration (FDA) regarding
the QMSR (quality system management regulation) and its incorporation by reference of the ISO 13485 standard, the Company believes it
will help streamline the Company’s transition into this revised FDA regulation.
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 8 2024 まで 9 2024
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 9 2023 まで 9 2024